DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Seribantumab is an investigational drug.
There have been 5 clinical trials for Seribantumab. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2017.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Ovarian Neoplasms. The leading clinical trial sponsors are Merrimack Pharmaceuticals, Sanofi, and [disabled in preview].
There are two US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Seribantumab
|Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer||Merrimack Pharmaceuticals||Phase 2|
|Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors||Sanofi||Phase 1|
|Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors||Merrimack Pharmaceuticals||Phase 1|
Top disease conditions for Seribantumab
Top clinical trial sponsors for Seribantumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Seribantumab||Start Trial||Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors||Merrimack Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Seribantumab||Start Trial||Salt of EGFR inhibitor, crystalline form and uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|